Cargando…
Janus Kinase inhibitors in the New Treatment Paradigms of Inflammatory Bowel Disease
This review provides guidance in the decision-making process regarding when to choose a janus kinase [JAK] inhibitor as medical treatment strategy. The focus will be on ulcerative colitis, because the only yet available JAK inhibitor, tofacitinib, has approval for use in ulcerative colitis. The guid...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7395309/ https://www.ncbi.nlm.nih.gov/pubmed/31922534 http://dx.doi.org/10.1093/ecco-jcc/jjaa003 |